HSIC

HSIC

Henry Schein is a global distributor of medical, dental, and veterinary supplies and equipment.
It is a critical connector in the healthcare supply chain, linking manufacturers with practitioner offices to ensure smooth operations.

$76.26 +0.44 (+0.58%)

Updated: January 14, 2026, 16:00 EST

Analyzed by Rockflow Bobby Quantitative Model ✓ Updated Daily

Investment Opinion: Should I buy HSIC Today?

Based on the provided data, here is a comprehensive analysis of Henry Schein, Inc. (HSIC).

Technical Analysis HSIC shows strong medium-term momentum with a significant 17% rally over the last quarter, heavily outperforming the market. While currently experiencing a minor pullback, its position in the upper part of its 52-week range suggests near-term upside may be limited, requiring potential consolidation. The stock's low beta indicates it is generally less volatile than the market, which can provide some stability.

Fundamental Analysis The company demonstrates modest growth, with sequential improvements in revenue and net income. However, underlying operational efficiency is a concern, evidenced by low profit margins, a weak return on equity, and a lengthy cash conversion cycle. Its financial health is stable with manageable debt, though cash flow generation relative to its obligations is low and warrants attention.

Valuation & Risk HSIC's valuation sends mixed signals; it looks reasonably priced on a PE and PS basis, but its very high EV/EBITDA ratio suggests a premium valuation that may not be justified by its growth profile. Risk is moderate, characterized by below-market volatility but a history of significant drawdowns, though the lack of substantial short interest points to stable investor sentiment.

Investment Recommendation HSIC presents a mixed picture. Its strong relative momentum and reasonable standard valuation multiples are positive factors. However, these are counterbalanced by weak operational efficiency metrics and a premium enterprise value multiple that questions its growth-adjusted value. For investors seeking a stable, low-volatility name with modest growth, it may be acceptable, but the current price level and operational challenges suggest it is likely a HOLD rather than a strong BUY. Investors might want to wait for a better entry point or clearer signs of improved operational execution.

CTA Banner

HSIC 12-Month Price Forecast

RockFlow Model Forecast: Three Scenarios for 2026

Based on the provided analysis, here is a 12-month outlook for Henry Schein (HSIC):

Catalysts: The primary positive catalyst is the stock's strong recent momentum, which could continue if the company demonstrates improved operational execution and a shortening of its cash conversion cycle. Any significant improvement in profit margins would be a key driver for a re-rating.

Risks: The main risks are operational inefficiency, as evidenced by weak ROE and low cash flow generation relative to obligations, and a premium valuation based on its EV/EBITDA ratio that may not be sustainable if growth remains modest. The current price near the high end of its 52-week range also suggests limited near-term upside without a fundamental improvement.

Outlook & Target: Given the mixed signals—reasonable standard valuation but premium enterprise value and operational challenges—the stock is likely to remain range-bound. A reasonable 12-month target range would be $70 - $85, reflecting the potential for consolidation with a slight upward bias if operational metrics stabilize. The recommendation aligns with a HOLD.

Wall Street Consensus

Most Wall Street analysts are optimistic about HSIC's 12-month outlook, with consensus target around $76.26, indicating expected upside potential.

Average Target
$76.26
16 analysts
Implied Upside
+0%
vs. current price
Analyst Count
16
covering this stock
Price Range
$61 - $99
Analyst target range
Buy Buy
6 (38%)
Hold Hold
9 (56%)
Sell Sell
1 (6%)

Bulls vs Bears: HSIC Investment Factors

Overall, HSIC has investment potential but also faces challenges. Here are key factors to weigh before investing.

Bullish Bullish
  • Strong Recent Price Surge: Stock rose 8% on high volume, indicating strong bullish momentum.
  • Positive Analyst Coverage Initiation: Barclays initiated coverage, providing a vote of confidence.
  • Robust Quarterly Earnings Beat: Q3 2025 sales significantly exceeded analyst consensus estimates.
  • Strategic Partnership with AWS: Cloud partnership could drive operational efficiency and future growth.
Bearish Bearish
  • Large Institutional Share Sale: Nuance Investments sold $38 million in shares, signaling caution.
  • Underperformance Versus Peers: Stock has lagged behind other healthcare stocks recently.
  • High Volatility Concern: Identified as a stock that may cause investor anxiety.
  • Valuation Questions Post-Gain: Recent 4.5% weekly gain raises attractiveness questions.
Reward Banner

HSIC Technical Analysis

Of course. Here is the technical analysis of HSIC's price performance:

Overall Assessment HSIC has demonstrated strong medium-term momentum but faces recent short-term headwinds, resulting in a mixed performance picture that leans positive due to its significant outperformance against the broader market over the last quarter.

Short-term Performance The stock's recent momentum has stalled, evidenced by a slight 1-month decline of -0.55%. However, this minor pullback follows a very strong 3-month rally of +17.42%. Crucially, the stock has significantly outperformed the market by over 14 percentage points during this period, indicating strong relative strength and investor confidence independent of general market movements.

Current Position Trading at $75.82, HSIC sits approximately 66% up from its 52-week low, positioning it in the upper-middle portion of its annual range ($60.56 - $82.49). While not at an extreme overbought level, its proximity to the 52-week high suggests limited immediate upside potential and a need for consolidation. The below-average beta of 0.884 implies lower volatility than the market, which may cushion against sharp declines.

📊 Beta
0.88
0.88x market volatility
📉 Max Drawdown
-24.3%
Largest decline past year
📈 52-Week Range
$61-$82
Price range past year
💹 Annual Return
+7.2%
Cumulative gain past year
Period HSIC Return S&P 500
1m -0.4% +1.3%
3m +20.7% +5.7%
6m +2.8% +10.6%
1y +7.2% +16.5%
ytd -0.7% +1.1%

HSIC Fundamental Analysis

Revenue & Profitability HSIC demonstrated modest revenue growth from $3.24B in Q2 to $3.34B in Q3 2025, with net income improving from $86M to $101M. However, profitability metrics remained constrained, as the net profit margin edged up only slightly to 3.0%, reflecting modest operational leverage amid competitive pressures.

Financial Health The company maintains a manageable debt level with a debt-to-equity ratio of 1.02, supported by an interest coverage of 5.4x. Operating cash flow coverage of debt is low at 0.05, indicating that while leverage is moderate, cash generation relative to obligations requires careful monitoring.

Operational Efficiency HSIC’s operational efficiency appears challenged, with a low return on equity of 3.0% and an asset turnover of 0.30. The extended cash conversion cycle of 80 days suggests working capital management could be improved to enhance capital productivity.

Quarterly Revenue
$3.3B
2025-09
Revenue YoY Growth
+5.2%
YoY Comparison
Gross Margin
30.7%
Latest Quarter
Free Cash Flow
$0.2B
Last 12 Months

Revenue & Net Income Trends (2 Years)

Revenue Breakdown

RockFlow Bobby - Your AI Investment Partner

Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions

Try Now & Get Tesla Stock Reward

Valuation Analysis: Is HSIC Overvalued?

Valuation Level: HSIC appears reasonably valued based on traditional metrics, with a forward PE of 19.7 and a modest PS ratio of 0.69 suggesting fair pricing relative to sales. However, concerning signals emerge from the elevated PEG ratio of 1.07, indicating limited growth-adjusted value, and a strikingly high EV/EBITDA of 44.1, which points to premium valuation when considering debt and operational earnings.

Peer Comparison: Without specific industry averages for comparison, a definitive peer assessment cannot be established. This analysis would typically benchmark HSIC's multiples against sector norms to determine relative valuation positioning, but such contextual evaluation requires accessible industry data for meaningful conclusions.

Current PE
21.7x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 15×-136×
vs. Industry Avg
N/A
Industry PE ~N/A×
EV/EBITDA
44.1x
Enterprise Value Multiple

Investment Risk Disclosure

Based on the provided metrics, HSIC exhibits moderate volatility risk. A Beta of 0.884 suggests the stock is generally less volatile than the broader market, typically moving about 88% as much. However, the 1-year maximum drawdown of -24.27% indicates it can still experience significant price declines from peak to trough.

The stock presents relatively low exposure to other common risks. The absence of any noteworthy short interest suggests a lack of widespread negative sentiment or bearish speculative pressure from short sellers. This, combined with the stock's moderate liquidity profile, indicates a stable ownership base and reduces the risk of a sharp, sentiment-driven selloff.

FAQs

Is HSIC a good stock to buy?

Neutral. The stock shows decent momentum and earnings beats, but its high EV/EBITDA ratio (44.1), modest profit margins (3.0%), and "Sell" analyst consensus temper enthusiasm. It may appeal to investors comfortable with moderate volatility and seeking exposure to healthcare distribution, but others should await clearer valuation improvements or stronger operational efficiency. Suitable for tactical traders rather than conservative long-term investors.

Is HSIC stock overvalued or undervalued?

HSIC appears modestly overvalued based on growth-adjusted metrics, though it looks fairly valued on traditional multiples. Its PEG ratio of 1.07 is above the ideal threshold of 1.0, and its EV/EBITDA of 44.1 is exceptionally high, indicating the market is pricing in significant future growth that current fundamentals may not support. Key metrics (P/E: 21.75; P/B: 2.23; P/S: 0.69) are not excessive in isolation, but weak profitability (3.0% net margin, 3.0% ROE) and low operational efficiency limit justification for a premium valuation. Given the low returns and strained cash flow coverage, the stock does not appear to offer a sufficient margin of safety.

What are the main risks of holding HSIC?

Of course. As a risk management analyst, here is an objective assessment of the key risks associated with holding HSIC stock, ordered by importance.

1. Operational Efficiency and Profitability Risk: The company faces a risk of sustained low profitability due to challenged operational efficiency, as evidenced by a low Return on Equity (3.0%) and a lengthy cash conversion cycle (80 days), which could limit its ability to generate significant value for shareholders and compete effectively. 2. Market Momentum Reversal Risk: Following a strong 17.42% rally over three months, the stock is now trading near the top of its 52-week range, creating a risk of a technical pullback or consolidation as the recent positive momentum may be exhausted. 3. Industry and Competitive Pressure Risk: The company operates in a competitive environment where it achieves only modest revenue growth and thin net profit margins (3.0%), indicating a risk that pricing power and market share are constrained by industry dynamics. 4. Financial Flexibility Risk: While the debt level is manageable, the very low operating cash flow coverage of debt (0.05x) poses a risk to financial flexibility, meaning the company has limited internally generated cash to service its debt obligations without relying on external financing or existing reserves.

What is the price forecast for HSIC in 2026?

Based on the provided analysis, my forecast for Henry Schein (HSIC) through 2026 is for moderate growth, contingent on operational improvements.

My target price range for 2026 is $80 - $95, with a base case of $85 and a bull case requiring successful execution. Key growth drivers include a significant shortening of the cash conversion cycle to improve cash flow, and margin expansion from better operational leverage. The main assumptions are that management stabilizes operational metrics and that the current premium valuation is sustained by demonstrating clearer growth. This forecast is highly uncertain, as it is sensitive to the company's ability to address its operational inefficiencies; failure to do so could result in the stock remaining range-bound near current levels.